C-reactive Protein Testing Market to Grow with a CAGR of 2.10% through 2030

Growing Incidence of Inflammatory and Infectious Diseases and Increasing Awareness of Preventive Healthcare are the major drivers for the Global C-reactive Protein Testing Market growth in the forecast period, 2026-2030

According to TechSci Research report, “C-reactive Protein Testing Market –Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2030F”, the Global C-reactive Protein Testing Market stood at USD1680.20 Million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 2.10% through 2026-2030.

The growth of the global C-reactive protein (CRP) testing market is largely driven by strategic collaborations and partnerships among leading companies. By merging expertise and resources, these alliances enhance technological advancements, expand market reach, and strengthen competitive positioning. The increasing prevalence of chronic diseases and the rising emphasis on early detection have further fueled demand for CRP testing across healthcare systems worldwide.

CRP testing is a widely used diagnostic tool that measures the levels of C-reactive protein in the blood, a key biomarker of inflammation produced by the liver. While CRP levels are typically low in healthy individuals, elevated levels indicate underlying inflammatory responses caused by infections, autoimmune diseases, or cardiovascular conditions. Healthcare providers utilize CRP testing to assess disease activity, monitor treatment efficacy, and make informed clinical decisions. This growing reliance on CRP as a diagnostic and monitoring tool has led to increased adoption in routine medical practice.

The healthcare industry’s rapid expansion, coupled with advancements in diagnostic technology, has significantly contributed to the market's growth. Technological innovations have improved the accuracy, efficiency, and accessibility of CRP testing, including the development of high-sensitivity CRP (hs-CRP) tests, point-of-care devices, and automated laboratory solutions. Additionally, the shift toward preventive healthcare has driven demand for CRP testing in cardiovascular risk assessment, as studies have established a strong correlation between elevated CRP levels and an increased risk of heart disease, stroke, and other cardiovascular events. As cardiovascular disease remains a leading cause of global mortality, CRP testing is increasingly being integrated into preventive screening programs and risk management strategies.

Beyond cardiovascular applications, CRP testing plays a crucial role in post-surgical care, helping clinicians monitor patients for complications related to inflammation or infection. Elevated post-operative CRP levels can serve as an early indicator of potential complications, allowing for timely intervention. Similarly, CRP testing is being utilized in managing conditions such as diabetes and cancer, where chronic inflammation is a key factor in disease progression. The growing emphasis on early detection and intervention has positioned CRP testing as a critical component of modern diagnostic protocols.

Governments and healthcare organizations worldwide are actively promoting CRP testing through various initiatives, including public health campaigns, routine screening programs, and funding for research and development. These initiatives aim to improve disease management, enhance preventive healthcare strategies, and increase awareness about the importance of inflammation markers in diagnosing and monitoring medical conditions. In addition, regulatory support and favorable reimbursement policies have facilitated the wider adoption of CRP testing, further driving market expansion.

Market revenue is primarily generated through the sale of CRP testing kits, reagents, and diagnostic equipment to hospitals, laboratories, and healthcare providers. With the increasing demand for CRP testing, companies are investing in innovation and expanding their product portfolios to cater to the evolving needs of healthcare professionals. Strategic partnerships between manufacturers, research institutions, and healthcare providers are fostering the development of sustainable diagnostic solutions that improve patient outcomes. As advancements in precision medicine, telehealth, and digital diagnostics continue to shape the industry, the CRP testing market is expected to witness sustained growth, playing a vital role in global healthcare management.

Browse over XX market data Figures and spread through xx Pages and an in-depth TOC on "Global C-reactive Protein Testing Market”

The Global C-reactive Protein Testing Market segmentation is based on Assay Type, Detection Range, disease Area, End-Use Industry, Company, and Regional distribution.

Based on its Disease area, The cardiovascular diseases (CVD) segment holds a dominant position in the global C-reactive protein (CRP) testing market, driven by the increasing prevalence of heart-related conditions and the growing emphasis on early disease detection and risk assessment. CRP testing plays a crucial role in cardiovascular healthcare by serving as a biomarker for systemic inflammation, which has been closely linked to the development and progression of CVD, including heart attacks, strokes, atherosclerosis, and coronary artery disease (CAD). Cardiovascular diseases are the leading cause of mortality worldwide, with millions of deaths attributed to heart-related conditions each year. Factors such as sedentary lifestyles, poor dietary habits, rising obesity rates, hypertension, diabetes, and smoking have contributed to the increasing incidence of CVD. As a result, healthcare providers are increasingly integrating CRP testing into routine cardiovascular screenings to identify individuals at risk before the onset of severe complications. The demand for high-sensitivity C-reactive protein (hs-CRP) tests has surged, as these advanced diagnostic tools can detect even low levels of inflammation that may indicate an elevated risk of cardiovascular events. Unlike traditional cholesterol tests, which primarily measure lipid levels, hs-CRP testing provides additional insights into vascular inflammation, allowing physicians to implement preventive measures, lifestyle interventions, and targeted therapies before major cardiovascular issues arise. 

Based on Region, The Asia Pacific region is expected to witness the fastest growth in the global C-reactive protein (CRP) testing market, driven by rising healthcare awareness, increasing prevalence of chronic diseases, advancements in diagnostic technologies, and expanding healthcare infrastructure. Several factors, including government initiatives, economic development, growing demand for preventive healthcare, and a rising aging population, contribute to the rapid market expansion in this region. Asia Pacific is experiencing a surge in chronic diseases, such as cardiovascular diseases (CVD), diabetes, autoimmune disorders, and cancer, which significantly drive demand for CRP testing as a diagnostic and monitoring tool. The growing incidence of inflammatory and infectious diseases, including tuberculosis (TB), pneumonia, and sepsis, has further fueled the adoption of CRP testing in hospitals and laboratories.

With cardiovascular diseases being the leading cause of mortality in countries like China, India, and Japan, high-sensitivity CRP (hs-CRP) testing is increasingly utilized in risk assessment, early detection, and preventive cardiology programs. Additionally, the burden of communicable diseases remains high in Southeast Asian nations, where CRP testing helps in early diagnosis and treatment monitoring

Some of the major companies operating in the Global C-reactive Protein Testing Market include:

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corp
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Merck KGaAA
• Zoetis Inc.
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“Certain regions, particularly North America, are projected to exert significant demand for C-reactive Protein Testing worldwide. The growth in the competitive landscape and the presence of well-established companies in the market, committed to enhancing their C-reactive Protein Testing productivity each year, are expected to contribute to a remarkable growth of the Global C-reactive Protein Testing Market in the forecast period," said Mr. Karan Chechi, Research Director of TechSci Research, a research-based Global management consulting firm.

"C-reactive Protein Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others), By Detection Range (hs-CRP, Conventional CRP, cCRP), By Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others), By End-Use Industry (Hospitals & Clinics, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others), By Region & Competition 2020-2030F", has evaluated the future growth potential of Global C-reactive Protein Testing Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide innovative market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global C-reactive Protein Testing Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com